Abstract-Recently, coronary microvascular function was documented to be impaired even in patients with prehypertension. However, the impact of antihypertensive level on improvement of coronary microvascular dysfunction in hypertensive patients remains to be established. We investigated the optimal blood pressure achieved with treatment of antihypertensive agents for improvement of coronary microvascular dysfunction in hypertensive patients. We prospectively studied 108 untreated hypertensive patients. All patients were treated with antihypertensive agents for approximately 12 months. Coronary flow reserve (CFR) was measured before and after treatment. The patients were divided into hypertensive, prehypertensive, and normal groups based on their average blood pressure during the treatment period. Pretreatment CFR was similar among all groups. CFR increased significantly in the normal group during the treatment period, but decreased significantly in the prehypertensive and hypertensive groups. This decrease was significantly greater in the hypertensive group than in the prehypertensive group. Multivariate analysis showed lowering blood pressure to normal level to be an independent determinant of improvement in CFR. The normal group was divided into normal-higher and normal-lower subgroups based on their average diastolic blood pressure during the treatment period. Increase in CFR was significantly greater in the normal-higher group than in the normal-lower group. These findings indicate that lowering blood pressure to a normal level is necessary to improve coronary microvascular dysfunction in hypertensive patients. Furthermore, raising diastolic blood pressure to a higher level within normal range has the most beneficial effect. However, as this study is based on observational design, it may have several limitations. (Hypertension. 2012;60:326-332.) • Online Data Supplement Key Words: antihypertensive treatment Ⅲ blood pressure Ⅲ coronary microvascular dysfunction Ⅲ echocardiography Ⅲ hypertension I t is well known that hypertensive patients have a decreased coronary flow reserve (CFR), even if they have normal epicardial coronary arteries. 1 In the absence of epicardial coronary stenosis, CFR is considered to be a marker of coronary microvascular dysfunction. A recent study documented that coronary microvascular function was impaired even in patients with prehypertension. 2 Antihypertensive treatment has been shown to improve coronary microvascular dysfunction 3-5 ; however, the optimal level for therapeutically lowering blood pressure (BP) remains to be established, with no previous data existing regarding the impact of antihypertensive level on coronary microvascular dysfunction. Recently, it was reported that CFR measured by transthoracic Doppler echocardiography had an excellent correlation with that measured by positron emission tomography, which was validated as the reference standard for measuring CFR. 6 In the present study, we examined the optimal level for therapeutic lowering of BP with antihypertensive agents for improving coronary microvascular dysfunction in hypertensive patients using transthoracic Doppler echocardiography.
I
t is well known that hypertensive patients have a decreased coronary flow reserve (CFR), even if they have normal epicardial coronary arteries. 1 In the absence of epicardial coronary stenosis, CFR is considered to be a marker of coronary microvascular dysfunction. A recent study documented that coronary microvascular function was impaired even in patients with prehypertension. 2 Antihypertensive treatment has been shown to improve coronary microvascular dysfunction [3] [4] [5] ; however, the optimal level for therapeutically lowering blood pressure (BP) remains to be established, with no previous data existing regarding the impact of antihypertensive level on coronary microvascular dysfunction. Recently, it was reported that CFR measured by transthoracic Doppler echocardiography had an excellent correlation with that measured by positron emission tomography, which was validated as the reference standard for measuring CFR. 6 In the present study, we examined the optimal level for therapeutic lowering of BP with antihypertensive agents for improving coronary microvascular dysfunction in hypertensive patients using transthoracic Doppler echocardiography.
Methods

Study Population
We screened 137 never-treated asymptomatic patients with essential hypertension. Exclusion criteria included the presence of any cardiac diseases, including coronary artery disease and any conduction abnormalities; any systemic or organic diseases, such as diabetes mellitus, chronic kidney disease, pulmonary, or hepatic diseases; life-limiting diseases; and inadequate echocardiographic image qual-ity. In addition, patients with left ventricular (LV) hypertrophy, defined as an LV mass index Ͼ111 g/m 2 in men and Ͼ106 g/m 2 in women, 7 were also excluded to avoid the confounding effects of LV hypertrophy on CFR. Based on these exclusion criteria, 15 patients were excluded, with 122 patients being enrolled onto the present study. Forty healthy volunteers served as normal controls. These controls were subjects with no history of cardiovascular disease, hypertension, or diabetes mellitus ascertained by recording their medical history and with no abnormal findings in a physical examination, including BP measurement, electrocardiography, and routine chemical analysis. The present study was approved by the institutional review committee, and written informed consent for participation was obtained from all subjects.
Study Protocol
After completing the pretreatment examination, antihypertensive treatment was started in all patients and continued for approximately 12 months. During the treatment period, the patients visited our hospital at 2-or 4-week intervals and underwent measurements of BP and heart rate at each visit. In accordance with the American Heart Association guidelines, BP was measured 3 times in a sitting position using a mercury sphygmomanometer after the patients had rested for 15 minutes and the average of the measurements was recorded. Heart rate was measured by pulse examination at the radial artery for 1 minute. At the posttreatment evaluation, patients were divided into 3 groups (hypertensive, prehypertensive, and normal groups) according to their average BP during the treatment period. The categorization was based on the BP categories proposed by the Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. 8 Each group was defined as follows: hypertensive group, average systolic BP (SBP) Ն140 mm Hg and/or average diastolic BP (DBP) Ն90 mm Hg; prehypertensive group, SBP 120 to 139 mm Hg and/or DBP 80 to 89 mm Hg; normal group, SBP Ͻ120 mm Hg and DBP Ͻ80 mm Hg. In the normal group, the median was also obtained from the individual average BP during the treatment period. Based on the median of SBP and DBP, patients in the normal group were divided into a lower half and an upper half (normal-SBP-higher group and normal-SBP-lower group, normal-DBP-higher group and normal-DBP-lower group). Categorization of the study patients was based on their BP during the treatment period, excluding pretreatment BP. Echocardiographic examination, including measurement of CFR, was performed before and after treatment. All antihypertensive agents were withdrawn for at least 5 half-live periods before the posttreatment examination to minimize acute effects of the medications on echocardiographic measurements.
Echocardiographic Examination
LV diameter and wall thickness were measured from M-mode echocardiography in the parasternal long axis view according to the criteria of the American Society of Echocardiography.
9 LV enddiastolic and end-systolic volume and LV ejection fraction were measured from the apical 2-and 4-chamber views using the Simpson's modified biplane method. 9 LV mass was determined by using the Penn convention and was indexed to body surface area. 10 Using pulsed-wave Doppler, peak velocity of the transmitral E wave and A wave (peak-E and peak-A), peak-E/peak-A ratio, deceleration time, and isovolumetric relaxation time of the transmitral E wave were measured. Each representative value was obtained from the average of 3 measurements. Pulsed-wave tissue Doppler of the septal and lateral mitral annulus was used for the measurement of early diastolic mitral annular peak velocity (E'). The average of the septal and lateral values was used. LV filling pressure was approximated from peak-E/E' ratio.
Measurement of CFR
Coronary blood flow in the middle to distal site of the left anterior descending coronary artery was visualized over the epicardial site of the LV anterior wall by color Doppler flow mapping from the apical approach. By placing the sample volume on the color signal, a biphasic pattern of coronary flow with larger diastolic and smaller systolic components was obtained. Dipyridamole infusion was performed at a rate of 0.56 mg/kg over 4 minutes 2 . Diastolic peak velocity of coronary flow (DPV) was measured at baseline and after dipyridamole infusion (Supplemental Figure S1 ). DPV was averaged over the technically best 3 cardiac cycles for each examination. CFR was defined as the ratio of hyperemic to baseline DPV. 11 Readers of the echocardiographic examination were blinded to the clinical data of the patients, including BP. Intraobserver and interobserver reproducibility for measurements of baseline and hyperemic DPV was examined in the controls. Intraobserver and interobserver correlation coefficients were 0.89 and 0.87, respectively, for baseline DPV, and 0.88 and 0.85, respectively, for hyperemic DPV.
Statistical Analyses
Continuous data were expressed as meanϮSD. Baseline data were compared using the x 2 test for categorical variables and unpaired t tests for continuous variables. Pretreatment and posttreatment data were compared by 1-way analysis of variance, followed by the Tukey's test or Kruskal-Wallis test. Univariate and multivariate regression analyses were performed to identify the independent determinants of improvement in CFR in the posttreatment evaluation. Clinical and echocardiographic variables that showed PϽ0.1 in the univariate analysis were included in the multivariate analysis. In the 2-tailed tests, PϽ0.05 was considered significant. Statistical analyses were performed using StatFlex version 5.0 for Windows.
Results
Clinical and Echocardiographic Characteristics of the Study Population
A total of 122 never-treated patients with essential hypertension were enrolled onto this study. During the follow-up period, 14 patients were excluded because they stopped visiting our institution, leaving a total of 108 patients. A consort diagram of the study patients is shown in Supplemental Figure S2 . The mean treatment period was 12.1Ϯ1.9 months. No patient had arrhythmia during the follow-up period. The patients were divided into the hypertensive group (nϭ23), prehypertensive group (nϭ45), and normal group (nϭ40) according to their average BP during the treatment period. The baseline clinical characteristics were similar among the 3 groups (Supplemental Table S1 ). There were no significant differences in baseline echocardiographic characteristics, including LV diastolic function, among the 3 groups (Supplemental Table S2 ). Compared with controls, thickness of the interventricular septum and LV posterior wall, left atrial dimension, and peak-E/E' were significantly greater, and E' was significantly lower, in the patient groups. During the follow-up period, thickness of the interventricular septum and LV posterior wall and LV mass index decreased significantly in the prehypertensive and normal groups, but remained unchanged in the hypertensive group. Left atrial dimension decreased significantly in the prehypertensive and normal groups, with a greater reduction in the normal group, but it did not change in the hypertensive group. E' increased significantly and peak-E/E' decreased significantly in the prehypertensive and normal groups, but these did not change in the hypertensive group. There were no significant differences in the classes of antihypertensive agents used among the 3 groups (Supplemental Table S3 ). Table 1 shows pretreatment and posttreatment CFR measurements. Pretreatment hyperemic DPV and CFR were significantly reduced in all patient groups compared with in controls, but were similar among the patient groups. Baseline DPV was similar between the patient groups and the controls. The posttreatment baseline DPV increased significantly in both the hypertensive and prehypertensive groups compared with the pretreatment values, but it remained unchanged in the normal group. Compared with the pretreatment hyperemic DPV, posttreatment values decreased significantly in the hypertensive group, increased significantly in the normal group, and remained unchanged in the prehypertensive group. CFR increased significantly in the normal group, but decreased significantly in both the hypertensive and prehypertensive groups. The decrease in CFR was significantly greater in the hypertensive group than in the prehypertensive group ( Figure 1 ).
Comparison of CFR Among Groups
Determinant of the Improvement of CFR
Variables with a PϽ0.1 in the univariate analysis were included in a multivariate analysis to determine the independent determinants of improvement in CFR over the treatment period. The univariate analysis included the following variables: patient group (normal, prehypertensive, and hypertensive groups); clinical characteristics, including age, sex, body mass index, pretreatment SBP, DBP, heart rate, smoking, lipid profile, and fasting glucose level; and pretreatment and posttreatment echocardiographic parameters, including LV chamber size, wall thickness, mass index, ejection fraction, left atrial dimension, and parameters of LV diastolic function. As shown in Table 2 , normal group, age, posttreatment left atrial dimension, LV mass index, and peak-E/E' were independent determinants of improvement in CFR.
Comparison of Hemodynamics and CFR in Normal Subgroups
The 40 patients in the normal group were divided into subgroups according to their average SBP (normal-SBPhigher and normal-SBP-lower groups) and DBP (normal-DBP-higher and normal-DBP-lower groups) during the treatment period. In the normal-SBP-higher group, average SBP was significantly higher than in the normal-SBP-lower group, but average DBP was similar (Supplemental Table S4 ). In the normal-DBP-higher group, both average SBP and DBP were Comparison of changed value of CFR during the treatment period among hypertensive, prehypertensive, and normal groups. CFR decreased during the treatment period in the hypertensive and prehypertensive groups; conversely, it increased in the normal group. The decrease in CFR was significantly greater in the hypertensive group than in the prehypertensive group. CFR indicates coronary flow reserve.
significantly higher than in the normal-DBP-lower group.
Baseline clinical characteristics as shown in Supplemental  Table S1 were similar among the subgroups (data not shown). Also, the echocardiographic characteristics as shown in Supplemental Table S2 were similar among the subgroups before and after treatment (data not shown). There were no significant differences in the classes of antihypertensive agents used among the subgroups (Supplemental Table S5 ). Pretreatment CFR was similar among the subgroups. Posttreatment CFR increased significantly compared with pretreatment CFR in the 4 subgroups ( Table 3 ). The increase in CFR was similar between the normal-SBP-higher and normal-SBP-lower groups, whereas it was significantly greater in the normal-DBP-higher group compared with the normal-DBP-lower group; this implies that there was less efficacy when DBP was lowered excessively (Figure 2) .
Discussion
The present study demonstrated that therapeutically lowering BP to normal level is necessary to improve coronary microvascular dysfunction in hypertensive patients. Our data also indicate that maintaining DBP at the higher level within normal range was most effective. Although several previous studies have shown that antihypertensive treatment improves impaired CFR in hypertensive patients, 5, [12] [13] [14] there is no previous data on the impact of antihypertensive level on changes in CFR. To the best of our knowledge, the present study is the first to establish the optimal antihypertensive level to improve coronary microvascular dysfunction in hypertensive patients with impaired CFR. In addition, this study also demonstrated that there was an inverted J-curve relationship between improvement in CFR and antihypertensive level of DBP. Inverted J-curve relationship means that improvement is greatest when DBP is lowered to the higher level within the normal range, with this improvement being attenuated when DBP is lowered to the lower or upper level than to the optimal level. Thus, excess reduction in DBP is less beneficial.
Hypertension and CFR
Several possible mechanisms have been proposed for the impairment of CFR in hypertensive patients. First, baseline coronary flow is increased because of increased tone of coronary resistance vessels caused by higher BP and extravascular compression in the presence of LV hypertrophy. Increased baseline coronary flow exhausts some of the reserve. 15 Second, the maximal coronary flow response to pharmacological stimuli may be limited by a reduction in the overall maximal cross-sectional area of the coronary microcirculatory bed. 16, 17 Third, an impairment of LV diastolic function may also play an important role, because coronary blood flow occurs predominantly during diastole. 18 A recent study showed that CFR was impaired in patients with not only hypertension, but also with prehypertension, although the impairment in prehypertensive patients was not as severe as in hypertensive patients. 2 In the present study, CFR was decreased in both hypertensive and prehypertensive groups over the treatment period, although LV hypertrophy and LV diastolic dysfunction did not deteriorate. This finding suggests that unless BP is lowered to normal level in hypertensive patients with impaired CFR, coronary microvascular dysfunction becomes worse, despite no progression of LV hypertrophy and diastolic dysfunction. This interpretation is consistent with the results of the multivariate analysis in our 
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study, which showed that normal group was an independent determinant of improvement in CFR. Reduced CFR is a sensitive indicator of hypertensive target-organ damage and signals a condition of increased risk for cardiovascular morbidity and mortality. 19, 20 Therefore, active searching and pharmacological intervention for impaired CFR is important to reduce cardiovascular risk in hypertensive patients. Previous studies have shown the beneficial effect of antihypertensive agents, such as angiotensin-converting enzyme inhibitor, angiotensin receptor blocker, and calcium antagonist, for improving impaired CFR in hypertensive patients. [3] [4] [5] [12] [13] [14] However, these studies did not investigate the relationship between antihypertensive level and improvement in CFR.
Optimal Antihypertensive Level for Improvement of CFR
The Comparison of Amlodipine versus Enalapril to Limit Occurrences of Thrombosis (CAMELOT) trial suggested that the most favorable rate of progression of coronary atherosclerosis was observed in patients whose BP fell within the normal level of the Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure category; also, the optimal BP goal might be substantially lower than 140/90 mm Hg to slow progression or induce regression of coronary atherosclerosis. 21 This study revealed that patients with hypertensive BP levels had the worst outcome, those with prehypertensive BP had an intermediate outcome, and those with normal BP had the best outcome, showing a trend for disease regression. These findings are consistent with epidemiological data demonstrating that coronary event rates are highest in patients with hypertension, intermediate in those with prehypertension, and lowest in those with normal BP. 22, 23 These findings suggest that optimal BP for patients with coronary artery disease may be as low as Ͻ120/80 mm Hg. In the present study, "remaining hypertensive" was associated with the greatest impairment of CFR, lowering to prehypertensive level was associated with an intermediate impairment, and lowering to normal level was associated with the least impairment. CFR decreased further during the follow-up period in hypertensive and prehypertensive groups despite receiving antihypertensive agents. Improvement in CFR was observed only in the normal group. There were no significant differences in the antihypertensive agents used among the patient groups. Our findings suggest that optimal BP may be lower than 120/80 mm Hg for improving coronary microvascular dysfunction, similar to slowing progression of coronary atherosclerosis. These findings also demonstrate that antihypertensive level is an important factor regardless of the particular antihypertensive agents.
Relationship Between Antihypertensive Level of DBP and Improvement in CFR
In the present study, it was noteworthy that the posttreatment increase in CFR was similar between the normal-SBP-higher group and the normal-SBP-lower group, whereas it was significantly greater in the normal-DBP-higher group than in the normal-DBP-lower group. This finding may have 2 important implications. First, antihypertensive level of SBP within the normal range may not be crucial for improving CFR. Second, excess lowering of DBP may attenuate improvement in CFR. Our results indicate that lowering DBP to the higher level within the normal range has the greatest benefit rather than lowering DBP above or below that level. In other words, there is an inverted J-curve relationship between antihypertensive level of DBP and improvement in CFR. The present study is the first to reveal an inverted J-curve relationship, indicating that excess reduction in DBP is less beneficial. In the present study, average DBP during the treatment period in the normal-DBP-higher and normal-DBP-lower groups was 76.3Ϯ1.3 mm Hg and 68.7Ϯ2.1 mm Hg, respectively. Although this difference appears to be minimal, it is statistically significant and may be of clinical importance. The optimal target range for lowering DBP may therefore be narrow for obtaining the greatest improvement in CFR.
Mechanisms of the Inverted J-Curve Relationship Between Antihypertensive Level of DBP and Improvement in CFR
In the present study, baseline DPV in addition to echocardiographic parameters, including LV diastolic function, were similar between the normal-DBP-higher and normal-DBPlower groups in posttreatment evaluation, whereas hyperemic DPV was greater in the former group. Hyperemic DPV is known to reflect the overall maximal cross-sectional area of the coronary microcirculatory bed. 16, 17 A possible explanation for the greater improvement in CFR in the normal-DBP-higher group may be attributable to a greater increase in hyperemic DPV, resulting from a greater increase in the coronary microcirculatory bed area during the treatment period compared with normal-DBP-lower group. Previous studies demonstrated that antihypertensive treatment induced an increase in myocardial capillary density, resulting in an increase in the overall cross-sectional area in hypertensive rats. 24, 25 However, these studies did not investigate the impact of antihypertensive level on the increase in myocardial capillary density. The coronary circulation is critically dependent on perfusion during diastole, so that it requires an adequate diastolic pressure. When coronary perfusion pressure is lowered to 40 to 50 mm Hg, diastolic blood flow in the coronary arteries ceases 26 ; our findings may reflect this physiological fact. Excess reduction in DBP may diminish antihypertensive treatment-induced increase in the coronary microcirculatory bed. Our findings may be related to the previous epidemiological reports that demonstrated a J-curve relationship between DBP and the risk of cardiovascular morbidity. 27, 28, 29 
Limitations
This study has several limitations. First, the follow-up duration was short. Because the follow-up period had a mean duration of 12.1 months, we cannot exclude the possibility that results of a long-term observation period may be different. Second, the time interval between antihypertensive medication dosing and BP measurements was not defined in the study protocol. Although BP was measured in the morning during the usual practice hours, the time interval varied among each patient. In the present study, several classes of antihypertensive drugs were used and each drug had a different pharmacokinetic half-life, so it was difficult to define the standardized time interval in all study patients. Third, the possibility that the antihypertensive drug classes influenced our findings cannot be excluded. However, all the antihypertensive drugs were withdrawn for at least 5 halflives before the CFR measurement. In addition, because there were no significant differences in the drug classes among each group, it is unlikely that our findings were influenced by the class of drug. Fourth, the CFR data were not corrected for heart rate, BP, LV size, and LV contraction. CFR is influenced by many covariates, particularly the above factors. Although these factors were not different among each group, it would be better if CFR was corrected for them so that CFR could be measured accurately. Fifth, although we speculate that there may have been a greater increase in coronary microcirculatory bed area resulting in a greater increase in CFR in normal-DBP-higher group, we did not perform a pathological assessment. However, we consider that an invasive examination, such as LV biopsy, is not justified ethically. Sixth, all study patients were Japanese; therefore, additional evaluations on racial differences are required. Finally, this study is based on observational design. The study patients were not randomly assigned to a target BP level. Although the baseline clinical and echocardiographic data were similar among each group, unknown factors may have affected the results.
Perspectives
The present study demonstrates that therapeutic lowering of BP to the normal level is necessary to improve coronary microvascular dysfunction in hypertensive patients. Moreover, achieving DBP at the higher level within normal range has the best effect, indicating that excess reduction in DBP may be less beneficial. This is contrary to the notion that lower is better. Although our study does not recommend undertreatment of antihypertensive therapy, we hope that our study provides a valuable insight for a legitimate debate as to the optimal antihypertensive level to achieve the greatest benefit for improving CFR in hypertensive patients.
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Novelty and Significance
What Is New?
• Lowering BP to the normal level is needed for improving coronary microvascular dysfunction.
• Lowered DBP and improvement in coronary microvascular dysfunction have an inverted J-curve relationship.
• This relationship is not affected by the class of antihypertensive agents.
What Is Relevant?
• Optimal antihypertensive level is suggested for improving coronary microvascular dysfunction in hypertensive patients.
• Attention to excess reduction in DBP may be necessary.
Summary
Lowering BP to normal level is necessary, and moreover, achieving DBP to upper level within normal range is most beneficial for improving coronary microvascular dysfunction in hypertensive patients. Table S1 . Clinical characteristics of each study group Table S2 . Pre-and post-treatment echocardiographic characteristics of each study group Table S3 . Use of antihypertensive agents of each group Table S4 . SBP and DBP during follow-up period in normal subgroups Table S5 . Use of antihypertensive agents of each normal subgroup There were no significant differences in the antihypertensive agents used among each group. There were no significant differences in the antihypertensive agents used among each subgroup.
